Retinal Telescreening for Diabetic Retinopathy

Policy # 00026
Original Effective Date: 08/25/2003
Current Effective Date: 08/09/2021

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services Are Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider retinal telescreening with digital imaging and manual grading of images as a screening technique for the detection of diabetic retinopathy to be **eligible for coverage.****

Based on review of available data, the Company may consider digital retinal imaging with image interpretation by artificial intelligence software that is approved by the U.S. Food and Drug Administration (eg, IDX-DR, EyeArt) for screening for diabetic retinopathy to be **eligible for coverage.****

Table PG1. American Diabetes Association Retinopathy Screening Recommendations

Patient Group	First Retinal Examination	Follow-Up
Adults with type 1 diabetes	Initial dilated and comprehensive eye examination by an ophthalmologist or optometrist within 5 y after the onset of diabetes	Yearly
Type 2 diabetes	Initial dilated and comprehensive eye examination by an ophthalmologist or optometrist at the time of diagnosis of diabetes	Yearly
Pregnancy in preexisting diabetes	Before pregnancy or in the first trimester	Every trimester and for 1 y postpartum as indicated by the degree of retinopathy

Retinal Telescreening for Diabetic Retinopathy

Policy # 00026
Original Effective Date: 08/25/2003
Current Effective Date: 08/09/2021

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers retinal telescreening for all other indications, including the monitoring and management of disease in individuals diagnosed with diabetic retinopathy to be **investigational.***

Background/Overview

Diabetic Retinopathy

Diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 years in the United States. The major risk factors for developing diabetic retinopathy are the duration of diabetes and severity of hyperglycemia. After 20 years of disease, almost all patients with type 1 and more than 60% of patients with type 2 diabetes will have some degree of retinopathy. Other factors that contribute to the risk of retinopathy include hypertension and elevated serum lipid levels.

Diabetic retinopathy progresses, at varying rates, from asymptomatic, mild non-proliferative abnormalities to proliferative diabetic retinopathy, with new blood vessel growth on the retina and posterior surface of the vitreous. The 2 most serious complications for vision are diabetic macular edema and proliferative diabetic retinopathy. At its earliest stage (non-proliferative retinopathy), the retina develops microaneurysms, intraretinal hemorrhages, and focal areas of retinal ischemia. With the disruption of the blood-retinal barrier, macular retinal vessels become permeable, leading to exudation of serous fluid and lipids into the macula (macular edema). As the disease progresses, retinal blood vessels are blocked, triggering the growth of new and fragile blood vessels (proliferative retinopathy). The new blood vessels that occur in proliferative diabetic retinopathy may fibrose and contract, resulting in tractional retinal detachments with significant vision loss. Severe vision loss with proliferative retinopathy arises from vitreous hemorrhage. Moderate vision loss can also arise from macular edema (fluid accumulating in the center of the macula) during the proliferative or non-proliferative stages of the disease. Although proliferative disease is the main cause of blinding in diabetic retinopathy, macular edema is more frequent and is the leading cause of moderate vision loss in people with diabetes.

Treatment
With early detection, diabetic retinopathy can be treated with modalities that can decrease the risk of severe vision loss. Tight glycemic and blood pressure control is the first line of treatment to control diabetic retinopathy, followed by laser photocoagulation for patients whose retinopathy is approaching the high-risk stage. Although laser photocoagulation is effective at slowing the progression of retinopathy and reducing visual loss, it causes collateral damage to the retina and does not restore lost vision. Focal macular edema (characterized by leakage from discrete microaneurysms on fluorescein angiography) may be treated with focal laser photocoagulation, while diffuse macular edema (characterized by generalized macular edema on fluorescein angiography) may be treated with grid laser photocoagulation. Corticosteroids may reduce vascular permeability and inhibit vascular endothelial growth factor production, but are associated with serious adverse events including cataracts and glaucoma, with damage to the optic nerve. Corticosteroids can also worsen diabetes control. Vascular endothelial growth factor inhibitors (eg, ranibizumab, bevacizumab, pegaptanib), which reduce permeability and block the pathway leading to new blood vessel formation (angiogenesis), are also used for the treatment of diabetic macular edema and proliferative diabetic retinopathy.

Digital Photography and Transmission Systems for Retinal Imaging
A number of photographic methods have been evaluated that capture images of the retina to be interpreted by expert readers, who may or may not be located proximately to the patient. Retinal imaging can be performed using digital retinal photographs with (mydriatic) or without (non-mydriatic) dilation of the pupil. One approach is mydriatic standard field 35-mm stereoscopic color fundus photography. Digital fundus photography has also been evaluated as an alternative to conventional film photography and has become the standard in major clinical trials. Digital imaging has the advantage of easier acquisition, transmission, and storage. Digital images of the retina can also be acquired in a primary care setting and evaluated by trained readers in a remote location, in consultation with retinal specialists.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)
Several digital camera and transmission systems (see Table 1 for examples) have been cleared for marketing by the U.S. FDA through the 510(k) process. Digital image storage and data

communication systems that are designed to be utilized with a variety of cameras have also been cleared for marketing by the FDA. FDA product codes: HKI and NFJ

Many artificial intelligence analysis systems are in use around the world. As of February 2021, 2 have received marketing clearance from the FDA (Table 2). In 2018, the FDA gave De Novo clearance for the automated retinal analysis system (IDx-DR) that uses artificial intelligence (DEN180001). IDx-DR is indicated "for use by health care providers to automatically detect more than mild diabetic retinopathy in adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. IDx-DR is indicated for use with the Topcon NW400. " EyeArt retinal analysis software (Eyenuk) received marketing clearance through the FDA's 510(k) pathway in 2020. It is indicated for use with the Canon CR-2 AF and Canon CR-2 Plus AF cameras in both primary care and eye care settings. Use of automated retinal analysis of images obtained with other cameras would be considered off-label. FDA product code: PIB

Table 1. Examples of Digital Camera and Transmission Systems Cleared by FDA for Retinal Telescreening

Camera and Transmission Systems	Manufacturer	FDA Clearance	Date
RetinaVue™‡ Network REF 901108 PACS Medical Image System	Welch Allyn	K181016	2018
IRIS Intelligent Retinal Imaging System™‡	Ora Inc.	K141922	2015
EyeSuite Imaging	Haag-Streit AG	K142423	2014
CenterVue Digital Retinography System (DRS)	Welch Allyn	K101935	2010
ImageNet™‡ Digital Imaging System	Topcon Medical Systems		2008
The Fundus AutoImagerä	Visual Pathways		2002
Zeiss FF450 Fundus Camera and the VISUPAC®‡ Digital Imaging System	Carl Zeiss Meditec		2001
DigiScope®‡	Eye Tel Imaging with Johns Hopkins Medicine		1999

FDA: Food and Drug Administration.

Table 2. Automated Analysis Systems

Automated Analysis Systems		Software Developer	FDA Clearance	Date
IDx-DR Artificial Intelligence Analyzer for the Topcon NW400		IDx, LLC	DEN180001	2018
EyeArt®‡		Eyenuk	K200667	2020

Rationale/Source

Retinopathy telescreening and risk assessment with digital imaging systems are proposed as an alternative to conventional dilated fundus examination in diabetic individuals. Digital imaging systems use a digital fundus camera to acquire a series of standard field color images and/or monochromatic images of the retina of each eye. Captured digital images may be transmitted via the Internet to a remote center for interpretation, storage, and subsequent comparison.

Summary of Evidence

For individuals who have diabetes without known diabetic retinopathy who receive digital retinal imaging with optometrist or ophthalmologist image interpretation, the evidence includes systematic reviews and a randomized controlled trial (RCT). Relevant outcomes are test validity, change in disease status, and functional outcomes. Data from systematic reviews have demonstrated there is concordance between direct ophthalmoscopy and grading by mydriatic or non-mydriatic photography and remote evaluation. An RCT that compared a telemedicine screening program with traditional surveillance found that patients who were randomized to the telemedicine arm were more likely to undergo screening (95% vs. 44%). There is limited direct evidence related to visual outcomes for patients evaluated with a strategy of retinal telescreening. However, given evidence from the Early Treatment Diabetic Retinopathy Study that early retinopathy treatment improves outcomes, coupled with studies showing high concordance between the screening methods used in the Early Treatment Diabetic Retinopathy Study, and an RCT demonstrating higher uptake of screening with a telescreening strategy, a strong chain of evidence can be made that telescreening is associated with improved health outcomes. Digital imaging systems have the additional advantages of short examination time and the ability to perform the test in the primary care physician setting.

For individuals who cannot or would not be able to access an eye care professional at the recommended screening intervals, the use of telescreening has a low risk and is very likely to increase the likelihood of retinopathy detection. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have diabetes without known diabetic retinopathy who receive digital retinal imaging with automated image interpretation, the evidence includes studies comparing the validity of automated scoring of digital images to human image grading. Relevant outcomes are test validity, change in disease status, and functional outcomes. Early detection of diabetic retinopathy is critical to vision preservation. The primary benefit of an automated screening system is to increase the rate of screening for a population that is seeing substantially increased rates of diabetes. A 2021 study found wide variability in diagnostic performance across 7 different artificial intelligence algorithms, indicating that each marketed software needs to be evaluated separately, in a diverse population, and with the specific camera and dilation specified. The version of the software, which can change frequently, is also key to evaluating performance characteristics. The pivotal study for the IDx-DR system met its predefined threshold when compared to the criterion standard of expert photography and image evaluation from a centralized site. The EyeArt versions 2.0 and 2.1.0 artificial intelligence software have been evaluated in a prospective pivotal trial and 2 large non-concurrent trials (30,000 and 100,000 encounters) in patients who had previously been screened as part of diabetic retinopathy screening programs. When used as an alternative to human grading, the sensitivity to detect diabetic retinopathy was above 90%. Detection of retinopathy (sensitivity) is the most critical feature for referral to an eye care specialist, and is highest in patients who have treatable disease. Annual screening would detect retinopathy as the disease progresses, mitigating the impact of false negatives. Automated annual screening at the same time as a routine diabetes check-up will improve health outcomes of patients with diabetes by increasing the rate of screening in accordance with the annual screening recommendation, thereby allowing earlier detection and treatment of diabetic retinopathy. This method minimizes delays in screening patients with diabetes, reduces strains on a limited resource of eye care specialists, and encourages referral to specialists for patients who screen positive for retinopathy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Additional Information

2011 Input

Clinical input was sought to help determine whether the use of retinal telescreening for individuals with diabetes with or without known diabetic retinopathy would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 2 academic medical centers and 1 physician specialty society.

For individuals without known diabetic retinopathy who receive retinal telescreening with or without dilation, clinical input supports this use provides a clinically meaningful improvement in net health outcome and indicates this use is consistent with generally accepted medical practice. Although evidence has shown that digital imaging without mydriasis leads to an increase in the proportion of ungradable photographs, practice guidelines and clinical input have supported the use of both dilated and undilated retinal telescreening.

For individuals with known diabetic retinopathy who receive retinal telescreening to monitor and manage disease, clinical input does not support a clinically meaningful improvement in net health outcome and does not indicate this use is consistent with generally accepted medical practice. Input was mixed on the use of retinal telescreening for monitoring and managing disease in individuals diagnosed with diabetic retinopathy. One reviewer commented that retinal telescreening could be useful for monitoring patients with stable disease, particularly in outlying areas where access to this technology exceeds access to ophthalmologists.

Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

Clinical input was sought to help determine whether the use of retinal telescreening for individuals with diabetes with or without known diabetic retinopathy would provide a clinically meaningful

improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from 2 academic medical centers and 1 physician specialty society.

For individuals without known diabetic retinopathy who receive retinal telescreening with or without dilation, clinical input supports this use provides a clinically meaningful improvement in net health outcome and indicates this use is consistent with generally accepted medical practice. Although evidence has shown that digital imaging without mydriasis leads to an increase in the proportion of ungradable photographs, practice guidelines and clinical input have supported the use of both dilated and undilated retinal telescreening.

For individuals with known diabetic retinopathy who receive retinal telescreening to monitor and manage disease, clinical input does not support a clinically meaningful improvement in net health outcome and does not indicate this use is consistent with generally accepted medical practice. Input was mixed on the use of retinal telescreening for monitoring and managing disease in individuals diagnosed with diabetic retinopathy. One reviewer commented that retinal telescreening could be useful for monitoring patients with stable disease, particularly in outlying areas where access to this technology exceeds access to ophthalmologists.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Diabetes Association
In 2020, the American Diabetes Association updated its guidelines on standards of medical care for diabetes. Included in the guidelines were specific recommendations for initial and subsequent screening examinations for retinopathy:

- "Adults with type 1 diabetes should have an initial dilated and comprehensive eye examination by an ophthalmologist or optometrist within 5 years after the onset of diabetes. (B)"

- "Patients with type 2 diabetes should have an initial dilated and comprehensive eye examination by an ophthalmologist or optometrist at the time of the diabetes diagnosis. (B)"
- "Eye examinations should occur before pregnancy or in the first trimester in patients with preexisting type 1 or type 2 diabetes, and then patients should be monitored every trimester and for 1 year postpartum as indicated by the degree of retinopathy. (B)"
- "If there is no evidence of retinopathy for one or more annual eye exams and glycemia is well controlled, then screening every 1–2 years may be considered. (B)"
- "Programs that use retinal photography (with remote reading or use of a validated assessment tool) to improve access to diabetic retinopathy screening can be appropriate screening strategies for diabetic retinopathy. Such programs need to provide pathways for timely referral for a comprehensive eye examination when indicated. (B)"

"Artificial intelligence systems that detect more than mild diabetic retinopathy and diabetic macular edema authorized for use by the FDA represent an alternative to traditional screening approaches. However, the benefits and optimal utilization of this type of screening have yet to be fully determined."

American Academy of Ophthalmology
A 2019 Preferred Practice pattern from the American Academy of Ophthalmology has provided the following on screening for diabetic retinopathy: “The purpose of an effective screening program for diabetic retinopathy is to determine who needs to be referred to an ophthalmologist for close follow-up and possible treatment and who may simply be screened annually. Some studies have shown that screening programs using digital retinal images taken with or without dilation may enable early detection of diabetic retinopathy along with an appropriate referral.”

American Telemedicine Association
In 2020, the American Telemedicine Association (ATA) updated their guidelines on the clinical, technical, and operational performance standards for ocular telehealth for diabetic retinopathy. Recommendations were based on reviews of evidence, medical literature, professional consensus, and a review that included open public comment. The guidelines stated that Early Treatment Diabetic Retinopathy Study 30°, stereo 7-standard field, color 35-mm slides have been the gold standard for evaluating diabetic retinopathy, but with the migration away from film photography, digital retinal images have become the norm for major clinical trials. The ATA recommends that telehealth

programs for diabetic retinopathy should demonstrate an ability to compare favorably with Early Treatment Diabetic Retinopathy Study film or digital photography as reflected in κ values for agreement of diagnosis, false-positive and false-negative readings, positive predictive value, negative predictive value, and sensitivity and specificity of referral thresholds.

The ATA notes limitations in sensitivity and specificity of smartphone platforms with a lack of standardization and a short product life cycle that create significant operational issues. Portable handheld imaging devices may suffer from some of the same limitations. The ATA considers computer algorithms to enhance digital retinal image quality or provide automated identification of retinal pathology to be emerging technologies.

Additional information on artificial intelligence for detection, classification, and diagnosis of diabetic retinopathy is included in the appendix of the guidelines.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination specific to retinal telescreening. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

There is a national coverage determination on intraocular photography, originally developed in 1979, which states:
"Intraocular photography is covered when used for the diagnosis of such conditions as macular degeneration, retinal neoplasms, choroid disturbances and diabetic retinopathy, or to identify glaucoma, multiple sclerosis and other central nervous system abnormalities. Make Medicare payment for the use of this procedure by an ophthalmologist [sic] in these situations when it is reasonable and necessary for the individual patient to receive these services."

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT04612868[a]	Pivotal Prospective Clinical Trial to Demonstrate the Efficacy and Safety of AEYE-DS Software Device for Automated Diabetic Retinopathy Detection From Digital Fundoscopic Images	350	Feb 2021
NCT04732208	Validation of an Artificial Intelligence Model for Diabetic Retinopathy Screening Using a Smartphone-based Fundus Camera in the UK Population	410	May 2021
NCT04627272[a]	An Evaluation of the Accuracy of AutoDx-DR, a Software Algorithm That Detects Diabetic Retinopathy From Retinal Images of Individuals With Diabetes	1539	Jul 2021
NCT04699864[a]	The Use of Artificial Intelligence in the Early Detection and the Follow-Up of Diabetic Retinopathy of Diabetic Patients Followed at the CHUM: Evaluation of NeoRetina Automated Algorithm (DIAGNOS Inc.)	630	Jan 2025
NCT03076697	Smartphone Screening for Eye Diseases	550	Aug 2025
Unpublished			
NCT03912961[a]	Comparative Analysis of Diabetic Retinopathy Images by Retina Specialists Versus EyeStar's Artificial Intelligence Software of Images Captured by Pictor Plus Retinal Camera	1034	Oct 2019 (completed)
NCT03602989[a]	A Prospective, Multi-center Clinical Study on the Application of An Artificial Intelligence Enabled	1000	Aug 2019

	Disease Detection Software to Diabetic Retinopathy Screening Based on Fundus Images		
NCT03572699	Simple, Mobile-based Artificial Intelligence AlgoRithms in the Detection of Diabetic ReTinopathy (SMART) Study	900	Oct 2018 (status unknown)
NCT03911323	A Prospective Clinical Study on the Real-world Diagnostic Effectiveness of Artificial Intelligence Algorithm in Diabetic Retinopathy Screening	1000	Oct 2020

NCT: national clinical trial.
a Industry sponsored or co-sponsored trial.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, "Retinal Telescreening for Diabetic Retinopathy", 9.03.13, April 2021.
2. Garg S, Davis RM. Diabetic retinopathy screening update. Clin Diabetes. 2009;27(4):140-145.
3. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. May 1991; 98(5 Suppl): 823-33. PMID 2062515
4. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. May 1991; 98(5 Suppl): 786-806. PMID 2062513
5. American Diabetes Association. Standards of Medical Care in Diabetes-2020 Abridged for Primary Care Providers. Clin Diabetes. Jan 2020; 38(1): 10-38. PMID 31975748
6. Moss SE, Klein R, Kessler SD, et al. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology. Jan 1985; 92(1): 62-7. PMID 2579361
7. Kinyoun JL, Martin DC, Fujimoto WY, et al. Ophthalmoscopy versus fundus photographs for detecting and grading diabetic retinopathy. Invest Ophthalmol Vis Sci. May 1992; 33(6): 1888-93. PMID 1582794
8. Shi L, Wu H, Dong J, et al. Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis. Br J Ophthalmol. Jun 2015; 99(6): 823-31. PMID 25563767

9. Bragge P, Gruen RL, Chau M, et al. Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol. Apr 2011; 129(4): 435-44. PMID 21149748
10. Mansberger SL, Sheppler C, Barker G, et al. Long-term Comparative Effectiveness of Telemedicine in Providing Diabetic Retinopathy Screening Examinations: A Randomized Clinical Trial. JAMA Ophthalmol. May 2015; 133(5): 518-25. PMID 25741666
11. Abramoff, MD, Lavin, PT, Birch, M, Shah, N, Folk, JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary. npj Digital Medicine (2018) 1:39 ; doi:10.1038/s41746-018-0040-6
12. U.S. Food and Drug Administration. EyeArt 510(k) Summary (K200667). August 3, 2020. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200667.pdf.
13. Bhaskaranand M, Ramachandra C, Bhat S, et al. The Value of Automated Diabetic Retinopathy Screening with the EyeArt System: A Study of More Than 100,000 Consecutive Encounters from People with Diabetes. Diabetes Technol Ther. Nov 2019; 21(11): 635-643. PMID 31335200
14. Heydon P, Egan C, Bolter L, et al. Prospective evaluation of an artificial intelligence-enabled algorithm for automated diabetic retinopathy screening of 30 000 patients. Br J Ophthalmol. Jun 30 2020. PMID 32606081
15. Lee AY, Yanagihara RT, Lee CS, et al. Multicenter, Head-to-Head, Real-World Validation Study of Seven Automated Artificial Intelligence Diabetic Retinopathy Screening Systems. Diabetes Care. Jan 05 2021. PMID 33402366
16. Kim TN, Aaberg MT, Li P, et al. Comparison of automated and expert human grading of diabetic retinopathy using smartphone-based retinal photography. Eye (Lond). Jan 2021; 35(1): 334-342. PMID 32341536
17. Abramoff MD, Lou Y, Erginay A, et al. Improved Automated Detection of Diabetic Retinopathy on a Publicly Available Dataset Through Integration of Deep Learning. Invest Ophthalmol Vis Sci. Oct 01 2016; 57(13): 5200-5206. PMID 27701631
18. American Academy of Ophthalmology. Diabetic Retinopathy Preferred Practice Pattern. 2019. https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp.
19. Horton MB, Brady CJ, Cavallerano J, et al. Practice Guidelines for Ocular Telehealth-Diabetic Retinopathy, Third Edition. Telemed J E Health. Apr 2020; 26(4): 495-543. PMID 32209018
20. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Intraocular Photography (80.6). 1979; https://www.cms.gov/medicare-coverage-database/details/ncd- details.aspx?NCDId=56&ncdver=1&bc=AgAAQAAAAAAA&.

Retinal Telescreening for Diabetic Retinopathy

Policy # 00026
Original Effective Date: 08/25/2003
Current Effective Date: 08/09/2021

Policy History

Original Effective Date: 08/25/2003
Current Effective Date: 08/09/2021

06/20/2003	Medical Policy Committee review
08/25/2003	Managed Care Advisory Council approval
11/02/2004	Medical Director review
11/16/2004	Medical Policy Committee review. Format revision. No substance change to policy.
11/29/2004	Managed Care Advisory Council approval
10/05/2005	Medical Director review
10/18/2005	Medical Policy Committee review Format revision. FDA information added to policy. Rationale/Source added from BCBSA policy. No substance change to policy.
10/27/2005	Quality Care Advisory Council approval
11/01/2006	Medical Director review
11/15/2006	Medical Policy Committee approval. Diabetic Association recommendations for diabetic retinopathy screening were added to policy.
11/07/2007	Medical Director review
11/15/2007	Medical Policy Committee approval. Policy statement unchanged.
11/05/2008	Medical Director review
11/18/2008	Medical Policy Committee approval. No change to coverage eligibility.
12/04/2009	Medical Director review
12/16/2009	Medical Policy Committee approval. No change to coverage eligibility.
12/01/2010	Medical Director review
12/15/2010	Medical Policy Committee approval. No change to coverage eligibility.
12/08/2011	Medical Policy Committee review
12/21/2011	Medical Policy Implementation Committee approval. Title changed from "Digital Imaging Systems for the Detection and Evaluation of Diabetic Retinopathy" to "Retinal Telescreening for Diabetic Retinopathy". Eligible for coverage statement revised to adopt the new policy title. Investigational statement added for all other indications of retinal telescreening. Background/Overview, Rationale and References revised and updated.
12/06/2012	Medical Policy Committee review
12/19/2012	Medical Policy Implementation Committee approval. No change to coverage.

Policy # 00026
Original Effective Date: 08/25/2003
Current Effective Date: 08/09/2021

12/12/2013	Medical Policy Committee review
12/18/2013	Medical Policy Implementation Committee approval. No change to coverage.
12/04/2014	Medical Policy Committee review
12/17/2014	Medical Policy Implementation Committee approval. No change to coverage.
12/03/2015	Medical Policy Committee review
12/16/2015	Medical Policy Implementation Committee approval. No change to coverage.
12/01/2016	Medical Policy Committee review
12/21/2016	Medical Policy Implementation Committee approval. No change to coverage. Chart revised.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
12/07/2017	Medical Policy Committee review
12/20/2017	Medical Policy Implementation Committee approval. No change to coverage.
12/06/2018	Medical Policy Committee review
12/19/2018	Medical Policy Implementation Committee approval. No change to coverage.
12/05/2019	Medical Policy Committee review
12/11/2019	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
07/02/2020	Medical Policy Committee review
07/08/2020	Medical Policy Implementation Committee approval. Added "Based on review of available data, the Company considers digital retinal imaging with automated image interpretation for the detection of diabetic retinopathy to be investigational." Chart updated.
12/11/2020	Coding update
07/01/2021	Medical Policy Committee review
07/14/2021	Medical Policy Implementation Committee approval. Automated image analysis may be considered eligible for coverage for screening for diabetic retinopathy.

Next Scheduled Review Date: 07/2022

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2020 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

Retinal Telescreening for Diabetic Retinopathy

Policy # 00026
Original Effective Date: 08/25/2003
Current Effective Date: 08/09/2021

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	92227, 92228 Code added eff 1/1/2021: 92229
HCPCS	No codes
ICD-10 Diagnosis	C92.01, C92.41, C92.51, C92.61, C92.A1, E08.11-E08.9, E09.11-E09.9, E10.311-E10.9, E11.0-E11.9, E13.0-E13.9

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
    1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
    2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
    3. Reference to federal regulations.

**Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

Retinal Telescreening for Diabetic Retinopathy

Policy # 00026
Original Effective Date: 08/25/2003
Current Effective Date: 08/09/2021

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.